Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar [Yahoo! Finance]
Alvotech (ALVO)
Company Research
Source: Yahoo! Finance
AVT03, a human monoclonal antibody, is Alvotech's biosimilar candidate to Amgen's Prolia and Xgeva (denosumab). Both Prolia and Xgeva are currently approved to treat various indications, including osteoporosis in postmenopausal women and prevention of skeletal-related events in adults with advanced malignancies. The collaboration agreement seeks to leverage Dr. Reddy's global commercial presence and Alvotech's proven capabilities in developing biosimilars for markets worldwide. Per the terms of the agreement, Dr. Reddy's will be responsible for the registration and commercialization of the AVT03 in the applicable markets, while Alvotech is tasked with the development and manufacturing of the potential product. Dr. Reddy's is liable to make an upfront payment to Alvotech, with additional payments upon certain regulatory and commercialization milestones as well as sales-based payments. The exact financial figures have not been disclosed by either of the companies. The license
Show less
Read more
Impact Snapshot
Event Time:
ALVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVO alerts
High impacting Alvotech news events
Weekly update
A roundup of the hottest topics
ALVO
News
- Alvotech and Stada add to strategic alliance through denosumab partnership [Seeking Alpha]Seeking Alpha
- Alvotech and STADA add to strategic alliance through denosumab partnership [Yahoo! Finance]Yahoo! Finance
- Alvotech and STADA add to strategic alliance through denosumab partnershipGlobeNewswire
- Alvotech enters refinancing agreement with $965M term loan facility [Seeking Alpha]Seeking Alpha
- Alvotech Announces Strategic Refinancing Agreement [Yahoo! Finance]Yahoo! Finance
ALVO
Earnings
- 5/21/24 - Miss
ALVO
Sec Filings
- 6/14/24 - Form 6-K
- 6/14/24 - Form 424B5
- 6/11/24 - Form 6-K
- ALVO's page on the SEC website